Stocktoria
Guardian Pharmacy Services, Inc. GRDN
Guardian Pharmacy Services, Inc. (GRDN) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $1.4B at a 3.4% net margin.
Beneish M-score: -2.95 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-17 | Truist Securities | Buy (main) |
| 2026-06-17 | B of A Securities | Buy (main) |
| 2026-05-07 | Oppenheimer | Outperform (main) |
| 2026-04-27 | B of A Securities | Buy (init) |
| 2026-04-13 | Truist Securities | Buy (main) |
| 2026-03-30 | Jefferies | Buy (init) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Retail Trade · percentile among 238 companies
Percentile vs other Retail Trade companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.148 |
| Retained earnings / assets | 0.161 |
| EBIT / assets | 0.176 |
| Equity / liabilities | 1.119 |
Sector peers · similar-size Retail Trade companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GRDN | Guardian Pharmacy Services, Inc. | 6/9 | 3.85 | 54.4 | +17.9% |
| YI | 111, Inc. | 2/9 | -5.73 | — | -9% |
| PETS | PETMED EXPRESS INC | 2/9 | -4.59 | — | -21.1% |
| RDGT | Ridgetech Inc. | 6/9 | 0.16 | — | +10.2% |
| CANN | TREES Corp (Colorado) | 3/9 | -16.65 | — | +34.9% |
| CVS | CVS HEALTH Corp | 5/9 | 0.99 | 75.3 | +7.8% |
| WMT | Walmart Inc. | 6/9 | 2.01 | 44 | +4.7% |
About Guardian Pharmacy Services, Inc.
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc. was founded in 2003 and is headquartered in Atlanta, Georgia.
FAQ
Is GRDN financially healthy?
Guardian Pharmacy Services, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does GRDN pay a dividend?
No, Guardian Pharmacy Services, Inc. does not currently pay a dividend.
How profitable is GRDN?
In FY2025, Guardian Pharmacy Services, Inc. had a net margin of 3.4% and a return on equity of 22.6%.
What is GRDN's P/E ratio?
Guardian Pharmacy Services, Inc.'s trailing price-to-earnings (P/E) ratio is about 54.4×, based on its latest annual earnings.
What is the analyst price target for GRDN?
The average Wall-Street price target for Guardian Pharmacy Services, Inc. is $47.00, about 21.8% above the recent price, from 6 analysts (consensus: strong buy).
Is GRDN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Guardian Pharmacy Services, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 54.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.